<style face="normal" font="default" size="100%">Erratum: The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis (Leukemia (2008) vol. 22 </style>

Drupal-Biblio